Stock listing
NASDAQ:KYTX Kyverna Therapeutics, Inc. Stock
Home listing (NASDAQ) of Kyverna Therapeutics, Inc.
Follow Kyverna Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:KYTX
$5.16 USD 0.00 (0.0%)
Close on Nov 4, 2026
- Day range
- $5.02 – $5.46 USDNov 4, 2026
- Volume
- 973,918 sharesNov 4, 2026
- Market cap
- $319.1M USDAt the close on Nov 4, 2026 · price × 61.84M shares outstanding
- 52-week range
- $5.02 – $13.67 USDLowest and highest trades, Nov 5, 2025 – Nov 4, 2026
- Traded on an average day
- $5.80M USDMedian day 778,700 shares · last 3 months, Aug 4, 2026 – Nov 4, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:KYTX · Home | $5.16 USD | 0.00 (0.0%) | 973,918 | $5.30 | $5.46 | $5.02 | $5.16 | Close on Nov 4, 2026 |
Daily closes
Last 3 months, Aug 4, 2026 – Nov 4, 2026 · NASDAQ:KYTX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $5.16 | 0.00 | 0.0% | $5.30 | $5.46 | $5.02 | 973,918 | |
| $5.16 | -0.06 | -1.1% | $5.28 | $5.48 | $5.12 | 703,002 | |
| $5.22 | -0.45 | -7.9% | $5.83 | $5.835 | $5.093 | 822,251 | |
| $5.67 | -0.18 | -3.1% | $5.74 | $5.87 | $5.55 | 640,116 | |
| $5.85 | -0.04 | -0.7% | $5.91 | $6.12 | $5.835 | 844,506 | |
| $5.89 | +0.26 | +4.6% | $5.58 | $5.935 | $5.56 | 995,061 | |
| $5.63 | +0.36 | +6.8% | $5.24 | $5.67 | $5.16 | 916,565 | |
| $5.27 | -0.12 | -2.2% | $5.35 | $5.40 | $5.18 | 809,993 | |
| $5.39 | -0.34 | -5.9% | $5.68 | $5.68 | $5.36 | 827,200 | |
| $5.73 | -0.11 | -1.9% | $5.825 | $5.985 | $5.67 | 519,400 | |
| $5.84 | -0.20 | -3.3% | $6.15 | $6.30 | $5.80 | 829,200 | |
| $6.04 | +0.21 | +3.6% | $5.83 | $6.20 | $5.80 | 766,300 | |
| $5.83 | +0.16 | +2.8% | $5.71 | $5.94 | $5.67 | 837,500 | |
| $5.67 | -0.30 | -5.0% | $5.94 | $6.05 | $5.64 | 724,500 | |
| $5.97 | +0.285 | +5.0% | $5.67 | $6.02 | $5.67 | 779,400 | |
| $5.685 | -0.085 | -1.5% | $5.76 | $5.845 | $5.61 | 1,275,700 | |
| $5.77 | -0.44 | -7.1% | $6.17 | $6.17 | $5.755 | 1,241,500 | |
| $6.21 | -0.18 | -2.8% | $6.34 | $6.46 | $6.19 | 417,100 | |
| $6.39 | +0.21 | +3.4% | $6.20 | $6.58 | $6.175 | 876,400 | |
| $6.18 | +0.01 | +0.2% | $6.06 | $6.216 | $5.96 | 1,317,000 | |
| $6.17 | +0.01 | +0.2% | $6.12 | $6.31 | $6.02 | 650,300 | |
| $6.16 | -0.16 | -2.5% | $6.38 | $6.45 | $6.13 | 739,400 | |
| $6.32 | +0.10 | +1.6% | $6.30 | $6.435 | $6.00 | 813,500 | |
| $6.22 | -0.30 | -4.6% | $6.62 | $6.754 | $6.17 | 1,180,600 | |
| $6.52 | -0.28 | -4.1% | $6.80 | $6.91 | $6.51 | 787,500 | |
| $6.80 | -0.04 | -0.6% | $6.875 | $7.10 | $6.73 | 746,200 | |
| $6.84 | +0.02 | +0.3% | $6.83 | $6.95 | $6.75 | 826,300 | |
| $6.82 | +0.01 | +0.1% | $6.72 | $6.95 | $6.65 | 997,000 | |
| $6.81 | -0.18 | -2.6% | $6.99 | $7.015 | $6.62 | 1,502,400 | |
| $6.99 | -0.08 | -1.1% | $7.80 | $7.92 | $6.675 | 3,275,100 | |
| $7.07 | -0.44 | -5.9% | $7.50 | $7.54 | $6.99 | 1,032,200 | |
| $7.51 | +0.39 | +5.5% | $7.18 | $7.59 | $7.11 | 836,500 | |
| $7.12 | -0.01 | -0.1% | $7.25 | $7.26 | $6.99 | 678,500 | |
| $7.13 | +0.09 | +1.3% | $7.02 | $7.19 | $7.00 | 960,600 | |
| $7.04 | +0.14 | +2.0% | $7.11 | $7.18 | $6.96 | 530,800 | |
| $6.90 | -0.06 | -0.9% | $7.02 | $7.155 | $6.855 | 685,700 | |
| $6.96 | -0.44 | -5.9% | $7.34 | $7.34 | $6.87 | 1,070,900 | |
| $7.40 | +0.14 | +1.9% | $7.25 | $7.49 | $7.21 | 533,900 | |
| $7.26 | -0.09 | -1.2% | $7.47 | $7.59 | $7.205 | 751,500 | |
| $7.35 | -0.29 | -3.8% | $7.51 | $7.53 | $7.34 | 854,400 | |
| $7.64 | -0.43 | -5.3% | $8.00 | $8.165 | $7.595 | 918,200 | |
| $8.07 | -0.18 | -2.2% | $8.17 | $8.21 | $7.97 | 586,200 | |
| $8.25 | -0.10 | -1.2% | $8.26 | $8.38 | $8.20 | 500,800 | |
| $8.35 | -0.265 | -3.1% | $8.71 | $8.78 | $8.28 | 595,300 | |
| $8.615 | +0.265 | +3.2% | $8.37 | $8.72 | $8.24 | 599,900 | |
| $8.35 | -0.125 | -1.5% | $8.27 | $8.42 | $7.60 | 1,782,300 | |
| $8.475 | +0.105 | +1.3% | $8.33 | $8.52 | $8.14 | 484,000 | |
| $8.37 | -0.27 | -3.1% | $8.52 | $8.55 | $8.31 | 524,900 | |
| $8.64 | +0.03 | +0.3% | $8.58 | $8.787 | $8.45 | 432,400 | |
| $8.61 | -0.23 | -2.6% | $8.81 | $8.839 | $8.504 | 413,800 | |
| $8.84 | +0.60 | +7.3% | $8.36 | $8.885 | $8.265 | 778,000 | |
| $8.24 | -0.18 | -2.1% | $8.32 | $8.40 | $8.00 | 565,100 | |
| $8.42 | +0.29 | +3.6% | $8.24 | $8.58 | $8.19 | 663,600 | |
| $8.13 | -0.74 | -8.3% | $8.73 | $8.76 | $8.11 | 953,900 | |
| $8.87 | +0.37 | +4.4% | $8.81 | $9.14 | $8.64 | 796,700 | |
| $8.50 | -0.45 | -5.0% | $8.80 | $8.83 | $8.361 | 851,500 | |
| $8.95 | +0.78 | +9.5% | $8.15 | $8.985 | $8.00 | 1,145,400 | |
| $8.17 | +0.09 | +1.1% | $8.10 | $8.29 | $7.80 | 580,000 | |
| $8.08 | +0.03 | +0.4% | $8.04 | $8.225 | $7.78 | 739,900 | |
| $8.05 | +0.03 | +0.4% | $7.92 | $8.665 | $7.78 | 1,031,500 | |
| $8.02 | +0.13 | +1.6% | $8.02 | $8.216 | $7.85 | 657,729 | |
| $7.89 | -0.07 | -0.9% | $7.97 | $8.17 | $7.89 | 553,982 | |
| $7.96 | +0.21 | +2.7% | $7.95 | $8.125 | $7.76 | 431,400 | |
| $7.75 | +0.11 | +1.4% | $7.64 | $7.84 | $7.55 | 505,300 | |
| $7.64 | -0.14 | -1.8% | $7.84 | $7.89 | $7.55 | 576,900 | |
| $7.78 | +0.27 | +3.6% | $7.55 | $7.815 | $7.51 | 564,100 |
- Ticker
- NASDAQ:KYTX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Oct 23, 2026
Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026
Latest deck · October 2026
Investor Presentation (October 2026)
Investor deck · 37 slides
Latest news
Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026
Oct 23, 2026
Closed $5.39 (-5.9%) on Oct 23, 2026
Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto
Oct 21, 2026
Closed $5.84 (-3.3%) on Oct 21, 2026
Kyverna Therapeutics to Present Positive Data in Stiff Person Syndrome and Progressive Multiple Sclerosis at MSToronto2026
Oct 7, 2026
Closed $6.17 (+0.2%) on Oct 7, 2026
Kyverna Therapeutics Reports Positive One-Year Data Demonstrating Durable Clinical Responses and Favorable Safety Profile for Miv-cel in Stiff Person Syndrome and Generalized Myasthenia Gravis
Sep 24, 2026
Closed $6.99 (-1.1%) on Sep 24, 2026
Kyverna Therapeutics to Present at Upcoming Investor Conferences
Sep 2, 2026
Closed $8.35 (-3.1%) on Sep 3, 2026
Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
Aug 11, 2026
Closed $8.05 (+0.4%) on Aug 12, 2026
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
Jul 27, 2026
Closed $7.92 (+6.9%) on Jul 27, 2026
Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition
Jun 22, 2026
Closed $8.30 (+2.9%) on Jun 22, 2026
Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis
Jun 3, 2026
Closed $7.82 (-1.0%) on Jun 3, 2026
Kyverna Therapeutics Names Greg Martini as Chief Financial Officer
May 18, 2026
Closed $8.54 (-10.0%) on May 18, 2026
Decks
Investor Presentation (October 2026)
Investor deck · 37 slides · October 2026
Corporate Update (September 2026)
Corporate update · 29 slides · Sep 24, 2026
Investor Presentation (September 2026)
Investor deck · 37 slides · September 2026
Jefferies Healthcare Conference 2026
Conference · 31 slides · June 2026
Kyverna Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 27 in the last 12 months · 66 in all · newest Oct 23, 2026 · oldest 2024
- Decks
- 11 decks · latest October 2026
Where Kyverna Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:KYTX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:KYTX | BOATS | United States | USD |
Log in to ask 6ix AI your own questions about Kyverna Therapeutics, Inc.